Publications by authors named "Alex Malinin"

Claim this Profile
T
The in vitro effects of niacin on platelet biomarkers in human volunteers.
Victor Serebruany, Alex Malinin, Daniel Aradi, Wiktor Kuliczkowski, Nicholas B Norgard

Thromb Haemost· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vitro effects of Xancor, a synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin-naïve and aspirin-treated subjects with multiple risk factors for vascular disease.
Victor Serebruany, Alex Malinin, Thomas Goodin, Fredric Pashkow

Am J Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aptamers: the emerging class of future anticoagulation for vascular disease.
Wiktor Kuliczkowski, James Floyd, Alex Malinin, Victor Serebruany

Expert Rev Cardiovasc Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Victor Serebruany, Alex Malinin, Fei-Hua Qiu, X-C Xu, Charles Kunsch

J Thromb Thrombolysis· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
Louis T van Zyl, Francois Lespérance, Nancy Frasure-Smith, Alex I Malinin, Dan Atar

J Thromb Thrombolysis· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.
Victor L Serebruany, Alex I Malinin, James J Ferguson, Javad Vahabi, Dan Atar

Fundam Clin Pharmacol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease.
Victor L Serebruany, Alex Malinin, Stephen Ong, Dan Atar

J Thromb Thrombolysis· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Victor L Serebruany, Alex I Malinin, Alex N Pokov, Daniel F Hanley

Clin Ther· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Victor L Serebruany, Alex I Malinin, Alex Pokov, Gregory Barsness, Dan F Hanley

Am Heart J· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan).
Victor L Serebruany, Alex I Malinin, Dan F Hanley

Thromb Haemost· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor.
Victor L Serebruany, Alex I Malinin, Charles H Hennekens

Cerebrovasc Dis· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study.
Dan Atar, Alex Malinin, Alex Pokov, Louis van Zyl, Nancy Frasure-Smith

Neuropsychopharmacology· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Victor L Serebruany, Alex Malinin, Christian Eisert, Stephen Ong

Expert Rev Cardiovasc Ther· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Victor L Serebruany, Alex I Malinin, Dan Atar

Cardiology· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials.
Victor Serebruany, Alex Malinin, Vadim Dragan, Dan Atar, Louis van Zyl

Clin Chem Lab Med· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Alex Malinin, Alex Pokov, Malcolm Spergling, Anthony Defranco, Kenneth Schwartz

Thromb Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Victor Serebruany, Alex Malinin, Alex Pokov, Umesh Arora, Dan Atar

Thromb Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?
Alex I Malinin, Benjamin R Oshrine, David C Sane, Christopher M O'Connor, Victor L Serebruany

Blood Coagul Fibrinolysis· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
Victor L Serebruany, Alex I Malinin, Dan Atar, Dan F Hanley

Am Heart J· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Victor Serebruany, Alex Malinin, Robert Scott

J Cardiovasc Pharmacol Ther· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?
Victor L Serebruany, Alex I Malinin, Deepak L Bhatt

Am J Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
Victor L Serebruany, Michael Miller, Alex N Pokov, Alex I Malinin, David R Lowry

Am J Cardiol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans.
Dan Atar, Alex Malinin, Aviv Takserman, Alex Pokov, Louis van Zyl

J Clin Psychopharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
Victor L Serebruany, Alex N Pokov, Alex I Malinin, Christopher O'Connor, Deepak L Bhatt

Am Heart J· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives.
Michael V Serebruany, Alex I Malinin, Victor L Serebruany

Expert Opin Pharmacother· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis